Abstract: The present invention provides methods for the determination of the viral titer of a culture of host animal host cells infected with a circovirus. The FACS-based methods of the invention may include determining the viability of the host cells in a cell culture medium supernatant and of those cells that remain adherent to a solid support. Detecting and measuring the percentage of cells that expressed the viral antigens ORF1 and ORF2 may determine the viral load of the cultured host cells. The yield of the virus may be established by the detection and measurement of both antigens in supernatant cells, for example 5 to 7 days from when the host cells are transferred to a serum free medium. The methods of the invention may yield rapid quantitative data. This allows the repeated in-process monitoring of the viral production throughout the incubation period, and ready selection of the most appropriate harvesting point.

Abstract: The present invention relates to a canine pre-proGHRH polypeptide, a canine mature GHRH peptide, an isolated polynucleotide which encodes the canine pre-proGHRH or the canine mature GHRH. The invention also encompasses vectors encoding and expressing the canine pre-proGHRH or the canine GHRH which can be used to treat disease and growth hormone deficiencies by gene therapy in vertebrates, in particular in dogs.

Abstract: A method of controlling parasites in or on an animal comprising administering to the animal a parasiticidally effective, substantially non-emetic 1-arylpyrazole.

Abstract: Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.

Abstract: The present invention relates to novel protozoal cyclic GMP dependent protein kinases and genes encoding same that have been isolated from Eimeria maxima and Plasmodium falciparum. Nucleic acid molecules having sequences that encode such proteins as well as antibodies raised against such proteins are also disclosed. These enzymes may be used in screening assays to identify potential antiprotozoal agents. As well, methods to obtain such nucleic acid molecules, proteins, antibodies and inhibitor are also provided as are therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and inhibitors as well as their use to protect animals from disease caused by parasites such as Eimeria maxima and Plasmodium falciparum.

Abstract: The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.

Abstract: What is described are a compound of the formula (I) Wherein A-B is —CH?CH— or —CH2—CH2—; n is 0 or 1; R1, is C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl; R2 and R3 for instance are either, (i) independently from each other for instance -Q, —C(?Y)-Q, or —C(?Y)—O-Q; or (ii) together form with the nitrogen atom to which they are bound a three- to seven-membered ring, (iii) together are ?C(R4)R5; R4 and R5 are, independently from each other, for instance -Q, —C(?Y)-Q, or —C(?Y)—O-Q; Y is O or S; Q is for instance H or unsubstituted or mono- to pentasubstituted C1-C12alkyl; or, if appropriate, an E/Z isomer, E/Z isomer mixture and/or tautomer thereof; a process for preparing these compounds, their isomers and tautomers and the use of these compounds, their isomers and tautomers; pesticidal compositions whose active compound is selected from these compounds and their tautomers; intermediates for the preparation of the said compounds of the formula (I), methods for the preparation of the compounds of the formula (

Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.

Abstract: The present invention provides methods for the determination of the viral titer of a culture of host animal host cells infected with a circovirus. The FACS-based methods of the invention may include determining the viability of the host cells in a cell culture medium supernatant and of those cells that remain adherent to a solid support. Detecting and measuring the percentage of cells that expressed the viral antigens ORF1 and ORF2 may determine the viral load of the cultured host cells. The yield of the virus may be established by the detection and measurement of both antigens in supernatant cells, for example 5 to 7 days from when the host cells are transferred to a serum free medium. The methods of the invention may yield rapid quantitative data. This allows the repeated in-process monitoring of the viral production throughout the incubation period, and ready selection of the most appropriate harvesting point.

Abstract: The present invention relates to a canine pre-proGHRH polypeptide, a canine mature GHRH peptide, an isolated polynucleotide which encodes the canine pre-proGHRH or the canine mature GHRH. The invention also encompasses vectors encoding and expressing the canine pre-proGHRH or the canine GHRH which can be used to treat disease and growth hormone deficiencies by gene therapy in vertebrates, in particular in dogs.

Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaracides.

Abstract: An in ovo jet injection apparatus and related methods for treating live eggs. The jet injection apparatus includes one or more jet injection delivery devices configured to deliver one or more treatment substances to predetermined areas of eggs using a high pressure stream of the treatment substance(s). Multiple treatment substances can be delivered so that they are spatially and/or temporally separate. The devices and methods of the invention enable the effective use of a plurality of treatment substances, including those that are effective when used alone but can be noxious if mixed. The methods and apparatus for the jet injection of substances into embryonic chicks reduce the risk of mechanical injury to the developing birds that would be caused by injection needles. The methods and apparatus of the invention can also reduce the introduction of an infection into the chicks.

Abstract: The present invention relates to a vaccine for coccidiosis in chickens prepared from four attenuated Eimeria species: E. acervulina, E. maxima, E. mitis and E. tenella. The vaccine was similar to or superior to other anticoccidial drugs in stimulating protective immunity against coccidiosis.

Abstract: This invention provides for inter alia, topical anthelmintic formulations which comprise a pharmaceutically active combination consisting of at least one macrocyclic compound and at least one compound selected from the group consisting of praziquantel, morantel and pyrantel, which are dissolved in a non-aqueous solvent or solvent mixture and optionally a thickening agent.

Abstract: A spray delivery system and methods of use thereof, suitable for delivering a fan-shaped vaccine spray to birds or chicks held within an open-topped container, comprising a cover, an elongated guide rail mounted thereon, and a spray head may move reversibly on the guide rail. The spray head comprises a spray nozzle assembly having a spray port and optionally a fan-shaped nozzle for delivering a fan-shaped fluid spray. The cover has an elongated slot that permits the spray nozzle assembly to extend below the plane of the cover while allowing the spray nozzle assembly to freely traverse the length of an open-topped container placed beneath the cover. By reversibly moving the spray head along the guide rail, the spray delivery system can deliver a substantially uniform fluid spray to an open-topped container with minimal overspray and reduced fluid wastage.

Abstract: The present invention relates to a vaccine for coccidiosis in chickens prepared from four attenuated Eimeria species: E. acervulina, E. maxima, E. mitis and E. tenella. The vaccine was similar to or superior to other anticoccidial drugs in stimulating protective immunity against coccidiosis.